| |
| |
|
| Insider
Information: |
Bentsur Ron |
| Relationship: |
Chairman & CEO, Direct... |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
4,184,530 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$52,263 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
4,184,530 |
|
|
| Total
Value |
$52,263 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Keryx Biopharmaceuticals Inc |
KERX |
Chief Executive Office... |
2015-04-06 |
777,209 |
|
0 |
Premium* |
|
|
XTL Biopharmaceuticals Ltd |
XTLBY |
CEO |
2007-08-21 |
20,101 |
|
0 |
Premium* |
|
|
Stemline Therapeutics Inc |
STML |
Director |
2020-06-10 |
0 |
|
0 |
Premium* |
|
|
Beyond Air Ord Shs |
XAIR |
Director |
2023-03-20 |
144,736 |
|
0 |
Premium* |
|
|
Nuvectis Pharma, Inc. |
NVCT |
Chairman & CEO, Direct... |
2024-03-18 |
3,242,484 |
2022-02-04 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
150 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| XTLBY |
XTL Biopharmaceuticals Lt... |
CEO |
• – – |
2006-08-25 |
4 |
B |
$2.98 |
$4,768 |
D/D |
1,600 |
4,822 |
2.66 |
- |
|
| XTLBY |
XTL Biopharmaceuticals Lt... |
CEO |
• – – |
2007-08-21 |
4 |
B |
$1.30 |
$19,863 |
D/D |
15,279 |
20,101 |
2.74 |
- |
|
| XTLBY |
XTL Biopharmaceuticals Lt... |
CEOOfficer |
• – – |
2006-08-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,222 |
|
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
CEOOfficer |
• – – |
2009-05-20 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
206,661 |
|
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • – |
2022-02-04 |
4 |
B |
$3.89 |
$1,048,625 |
D/D |
212,500 |
2,777,959 |
2.81 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • – |
2022-02-07 |
4 |
B |
$3.93 |
$104,520 |
D/D |
20,000 |
2,797,959 |
2.81 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • – |
2022-02-10 |
4 |
B |
$6.34 |
$53,890 |
D/D |
8,500 |
2,806,459 |
2.81 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • – |
2022-02-14 |
4 |
B |
$5.88 |
$47,040 |
D/D |
8,000 |
2,814,459 |
2.81 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-03-17 |
4 |
B |
$7.63 |
$53,410 |
D/D |
7,000 |
2,821,459 |
3.23 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-03-28 |
4 |
B |
$7.05 |
$28,200 |
D/D |
4,000 |
2,825,459 |
3.23 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
120,000 |
2,945,459 |
0 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-05-12 |
4 |
B |
$14.88 |
$208,047 |
D/D |
12,245 |
2,957,704 |
3.23 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-05-13 |
4 |
B |
$18.10 |
$12,670 |
D/D |
700 |
2,958,404 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-05-16 |
4 |
B |
$19.32 |
$19,320 |
D/D |
1,000 |
2,959,404 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-05-17 |
4 |
B |
$19.77 |
$6,245 |
D/D |
310 |
2,959,714 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-05-18 |
4 |
B |
$18.49 |
$32,910 |
D/D |
1,700 |
2,961,414 |
3.23 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-05-19 |
4 |
B |
$18.95 |
$3,790 |
D/D |
200 |
2,961,614 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-05-20 |
4 |
B |
$16.28 |
$16,280 |
D/D |
1,000 |
2,962,614 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-05-26 |
4 |
B |
$15.90 |
$7,950 |
D/D |
500 |
2,963,114 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-05-27 |
4 |
B |
$15.74 |
$7,870 |
D/D |
500 |
2,963,614 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-06-22 |
4 |
B |
$13.10 |
$1,310 |
D/D |
100 |
2,963,714 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-06-23 |
4 |
B |
$11.40 |
$2,280 |
D/D |
200 |
2,963,914 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-06-24 |
4 |
B |
$12.18 |
$4,872 |
D/D |
400 |
2,964,314 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-06-28 |
4 |
B |
$11.82 |
$3,546 |
D/D |
300 |
2,964,614 |
3.15 |
- |
|
| NVCT |
Nuvectis Pharma, Inc. |
Chairman & CEO |
• • • |
2022-06-29 |
4 |
B |
$11.62 |
$42,994 |
D/D |
3,700 |
2,968,314 |
3.23 |
- |
|
150 Records found
|
|
Page 1 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
